Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study

Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2012-10, Vol.44 (8), p.2449-2451
Hauptverfasser: Salvalaggio, P.R, Felga, G.E, Afonso, R.C, Ferraz-Neto, B.H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2451
container_issue 8
container_start_page 2449
container_title Transplantation proceedings
container_volume 44
creator Salvalaggio, P.R
Felga, G.E
Afonso, R.C
Ferraz-Neto, B.H
description Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase >2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P < .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P < .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.
doi_str_mv 10.1016/j.transproceed.2012.08.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1082238265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134512008408</els_id><sourcerecordid>1082238265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoMo7rj6F6QIgjet-Won3QthmF13hYEFZ701pMnpkrGTjkk70H_vqTOL4pVXSchzznt4OIS8Y7RglFUfd8UQTUiH2FsAV3DKeEFVQSl_RhZMLUXOKy6ekwWlkuVMyPKCvEppR_HNpXhJLrigvKrYckG-35jYTdmq6_rHaNohu55SOwY7-D5kJrhs448Qs4ffgZ0JQ3Y_DrbfQ7rKVtnWh8cOsjWEAaGvMMQ-HQCLj5Bth9FNr8mL1nQJ3pzPS_Lt883D-i7f3N9-Wa82uZVVOeSyVLK2snE1Ew2vXGNr5kqQrVKAF1OyWjWicQKHBivrZdkurXBGAmetZVRckg-nvijl5whp0HufLHQ4MfRj0owqzoXiVYno1Qm1OGyK0OpD9HsTJ4T07Ffv9N9-9exXU6XRLxa_PeeMzR7_nkqfhCLw_gyYZE3XYiPr0x-uKqs5A7nrEwdo5egh6mQ9BAvORxSoXe__b55P_7SxnQ8ek3_ABGnXjzGgd810whq9nTdiXgjGKVWSKvELSRq1UA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1082238265</pqid></control><display><type>article</type><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</creator><creatorcontrib>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</creatorcontrib><description>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase &gt;2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P &lt; .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P &lt; .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2012.08.002</identifier><identifier>PMID: 23026617</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Alanine Transaminase - blood ; Aspartate Aminotransferases - blood ; Bilirubin - blood ; Biological and medical sciences ; Biomarkers - blood ; Brazil - epidemiology ; Chi-Square Distribution ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Survival ; Humans ; Incidence ; Kaplan-Meier Estimate ; Liver Transplantation - adverse effects ; Liver Transplantation - mortality ; Male ; Medical sciences ; Primary Graft Dysfunction - blood ; Primary Graft Dysfunction - epidemiology ; Primary Graft Dysfunction - mortality ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Time Factors ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2012-10, Vol.44 (8), p.2449-2451</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</citedby><cites>FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2012.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26561016$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23026617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salvalaggio, P.R</creatorcontrib><creatorcontrib>Felga, G.E</creatorcontrib><creatorcontrib>Afonso, R.C</creatorcontrib><creatorcontrib>Ferraz-Neto, B.H</creatorcontrib><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase &gt;2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P &lt; .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P &lt; .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</description><subject>Alanine Transaminase - blood</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Bilirubin - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Brazil - epidemiology</subject><subject>Chi-Square Distribution</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Transplantation - adverse effects</subject><subject>Liver Transplantation - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Primary Graft Dysfunction - blood</subject><subject>Primary Graft Dysfunction - epidemiology</subject><subject>Primary Graft Dysfunction - mortality</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Time Factors</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl2L1DAUhoMo7rj6F6QIgjet-Won3QthmF13hYEFZ701pMnpkrGTjkk70H_vqTOL4pVXSchzznt4OIS8Y7RglFUfd8UQTUiH2FsAV3DKeEFVQSl_RhZMLUXOKy6ekwWlkuVMyPKCvEppR_HNpXhJLrigvKrYckG-35jYTdmq6_rHaNohu55SOwY7-D5kJrhs448Qs4ffgZ0JQ3Y_DrbfQ7rKVtnWh8cOsjWEAaGvMMQ-HQCLj5Bth9FNr8mL1nQJ3pzPS_Lt883D-i7f3N9-Wa82uZVVOeSyVLK2snE1Ew2vXGNr5kqQrVKAF1OyWjWicQKHBivrZdkurXBGAmetZVRckg-nvijl5whp0HufLHQ4MfRj0owqzoXiVYno1Qm1OGyK0OpD9HsTJ4T07Ffv9N9-9exXU6XRLxa_PeeMzR7_nkqfhCLw_gyYZE3XYiPr0x-uKqs5A7nrEwdo5egh6mQ9BAvORxSoXe__b55P_7SxnQ8ek3_ABGnXjzGgd810whq9nTdiXgjGKVWSKvELSRq1UA</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Salvalaggio, P.R</creator><creator>Felga, G.E</creator><creator>Afonso, R.C</creator><creator>Ferraz-Neto, B.H</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121001</creationdate><title>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</title><author>Salvalaggio, P.R ; Felga, G.E ; Afonso, R.C ; Ferraz-Neto, B.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-45849c4bd913b26dbc91d5e4f88e1d5a5198b3bd3661ec4975f7c3da4e21fc103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Alanine Transaminase - blood</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Bilirubin - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Brazil - epidemiology</topic><topic>Chi-Square Distribution</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Transplantation - adverse effects</topic><topic>Liver Transplantation - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Primary Graft Dysfunction - blood</topic><topic>Primary Graft Dysfunction - epidemiology</topic><topic>Primary Graft Dysfunction - mortality</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Time Factors</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salvalaggio, P.R</creatorcontrib><creatorcontrib>Felga, G.E</creatorcontrib><creatorcontrib>Afonso, R.C</creatorcontrib><creatorcontrib>Ferraz-Neto, B.H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salvalaggio, P.R</au><au>Felga, G.E</au><au>Afonso, R.C</au><au>Ferraz-Neto, B.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>44</volume><issue>8</issue><spage>2449</spage><epage>2451</epage><pages>2449-2451</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Background Early allograft dysfunction (EAD) had been related to poor transplant outcomes during the early years of liver transplantation. We sought to determine the incidence of EAD at our unit and to evaluate its impact on posttransplant outcomes. Methods This single-center retrospective study included primary deceased donor liver grafts transplanted under the Model for End-Stage Liver Disease system. EAD was defined as a peak values of aminotransferase &gt;2000 IU/mL during the first week or an International Normalized Ratio of ≥1.6 and/or bilirubin ≥10 mg/dL at day 7. The main endpoints were patient and graft survivals. Results Patients with versus without EAD showed similar recipient characteristics. Donors who experienced EAD who comprises 56% of recipients were heavier with larger body mass indices. EAD was an independent risk factor for allograft loss. Most retransplants were performed early due to nonfunction. The primary nonfunction rate among subjects with versus without EAD were 7% and 12% respectively ( P &lt; .05). Patient survival among those with EAD was 87.4%, while without EAD it was 90% ( P = NS) with graft survivals of 81.4% and 88.7% respectively ( P &lt; .05). Conclusion Patients with EAD show a significantly higher risk for allograft loss, but with a comparable survival after transplantation. Despite their worse outcomes, it seems that not all of these recipients behave equally.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23026617</pmid><doi>10.1016/j.transproceed.2012.08.002</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2012-10, Vol.44 (8), p.2449-2451
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_1082238265
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Alanine Transaminase - blood
Aspartate Aminotransferases - blood
Bilirubin - blood
Biological and medical sciences
Biomarkers - blood
Brazil - epidemiology
Chi-Square Distribution
Female
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Graft Survival
Humans
Incidence
Kaplan-Meier Estimate
Liver Transplantation - adverse effects
Liver Transplantation - mortality
Male
Medical sciences
Primary Graft Dysfunction - blood
Primary Graft Dysfunction - epidemiology
Primary Graft Dysfunction - mortality
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Time Factors
Tissue, organ and graft immunology
Treatment Outcome
title Early Allograft Dysfunction and Liver Transplant Outcomes: A Single Center Retrospective Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T23%3A39%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20Allograft%20Dysfunction%20and%20Liver%20Transplant%20Outcomes:%20A%20Single%20Center%20Retrospective%20Study&rft.jtitle=Transplantation%20proceedings&rft.au=Salvalaggio,%20P.R&rft.date=2012-10-01&rft.volume=44&rft.issue=8&rft.spage=2449&rft.epage=2451&rft.pages=2449-2451&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2012.08.002&rft_dat=%3Cproquest_cross%3E1082238265%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1082238265&rft_id=info:pmid/23026617&rft_els_id=S0041134512008408&rfr_iscdi=true